Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease.
about
Dalcetrapib: no off-target toxicity on blood pressure or on genes related to the renin-angiotensin-aldosterone system in ratsDalcetrapib: a review of Phase II data.Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors.Therapeutic approaches to drug targets in atherosclerosis.Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial.Monogenic causes of elevated HDL cholesterol and implications for development of new therapeutics.Distinct HDL subclasses present similar intrinsic susceptibility to oxidation by HOCl.A reduction of CETP activity, not an increase, is associated with modestly impaired postprandial lipemia and increased HDL-cholesterol in adult asymptomatic womenThe CETP I405V polymorphism is associated with an increased risk of Alzheimer's disease.High Density Lipoprotein (HDL) Modulation Targets.Patient considerations and clinical impact of cholesteryl ester transfer protein inhibitors in the management of dyslipidemia: focus on anacetrapib.High level of serum cholesteryl ester transfer protein in active hepatitis C virus infection.Targeting high-density lipoprotein cholesterol in the management of cardiovascular disease.Human cholesterol metabolism and therapeutic molecules.Adipose tissue dysfunction in obesity, diabetes, and vascular diseases.Mechanism of inhibition defines CETP activity: a mathematical model for CETP in vitro.CETP TaqIB Polymorphism, Serum Lipid Levels And Risk Of Atrial Fibrillation: A Case-Control Study.An abundant dysfunctional apolipoprotein A1 in human atheroma.Cholesteryl ester transfer protein inhibition in cardiovascular risk management: ongoing trials will end the confusion.On- and off-target pharmacology of torcetrapib: current understanding and implications for the structure activity relationships (SAR), discovery and development of cholesteryl ester-transfer protein (CETP) inhibitors.Mendelian randomization studies in coronary artery disease.Underappreciated opportunities for high-density lipoprotein particles in risk stratification and potential targets of therapy.Association Studies of Specific Cholesterol Related Genes (APOE, LPL, and CETP) with Lipid Profile and Memory Function: A Correlative Study Among Rural and Tribal Population of Dharmapuri District, India.Navigating the Future of Cardiovascular Drug Development-Leveraging Novel Approaches to Drive Innovation and Drug Discovery: Summary of Findings from the Novel Cardiovascular Therapeutics Conference.Diverse Molecular Targets for Chalcones with Varied Bioactivities.HDL2 of heavy alcohol drinkers enhances cholesterol efflux from raw macrophages via phospholipid-rich HDL 2b particles.Elevated cholesteryl ester transfer protein (CETP) activity, a major determinant of the atherogenic dyslipidemia, and atherosclerotic cardiovascular disease in South Asians.Effect of crocin, a carotenoid from saffron, on plasma cholesteryl ester transfer protein and lipid profile in subjects with metabolic syndrome: A double blind randomized clinical trial.Lipid transfer protein activities in subjects with impaired glucose tolerance.Dietary calcium decreases plasma cholesterol by down-regulation of intestinal Niemann-Pick C1 like 1 and microsomal triacylglycerol transport protein and up-regulation of CYP7A1 and ABCG 5/8 in hamsters.Mycophenolate mofetil as an immunomodulatory silver bullet in atherogenesis?
P2860
Q33569541-B9FA47A5-2F99-47F7-BA9C-CBBBCB3D9389Q33577236-E440DA4F-BE7C-426F-A705-E6FF6EEC2EECQ33590777-8260D19F-1411-46B9-A7DF-694F813E769EQ33906710-BDDA381B-09CD-4ED5-AB9E-9B203C41F17BQ34120778-651A9C57-8B31-45AF-AE2B-217198C9D27DQ34441411-FDABB394-1380-4F2B-940B-73CA09E4CB88Q34758389-22FA863F-91BA-4F03-BD53-E9F1D2B433E5Q35074336-8CB65D86-E882-4154-9D90-FC6F6F79948DQ35836521-374DD2A6-8E44-46F4-A293-33690D02C17FQ36053317-AA287FE4-BD6E-4F5B-820A-9AD67CB962CBQ36197709-533EAFE0-B279-4FE6-8C01-4E1F0D5432F5Q36590937-721DC051-083B-4700-9A97-4780B0442F7DQ36992708-F8EA27A0-8A3D-48D2-A8E4-0F8C4B57DE83Q37047547-499F0127-4F3A-4B1C-929F-0C3984FF3FBAQ37262617-EEBBEEA2-DBCD-49BC-AF5D-C9C086609206Q37382142-07B8FB64-1AD6-4306-A3CA-610DA3266C4DQ37469031-B7C5571E-295E-4FB3-80DA-4AD4732B4829Q37581580-1866EE9A-C780-4D99-A685-E09D87A71A00Q37774393-3035E976-F005-4D65-98FF-07E2D09DDF8CQ37987207-B03A1BCF-6BCD-455C-809E-46750F88175AQ38219388-D734FB58-C506-4EE9-8AE6-49F93E8874B9Q38363617-59D31B71-2F03-4F3E-B081-010C81CB9F57Q38640748-3C08CFBF-46AE-4B28-8BEA-803DD7A55C37Q38653210-88A7E42C-930F-49DD-935D-35F4C558E35DQ38707609-C34B65A1-C6DE-4BD0-9DB5-86F51EA23640Q39979442-6DF48BA1-7C5E-471A-8EE2-690AD1F94DCBQ44873060-5B1483B1-07E6-457F-BD14-CAD4F37AB845Q49279420-8604EDE7-695A-4520-93F3-32E56861EB62Q51477581-3EF520B5-1AA4-4142-821F-0427F66E7FCBQ51772227-84937192-1539-4CD1-BEC8-E2BB7BACB0ADQ57839864-CD5EA694-48B9-40B0-9BFA-0AE50359BAE1
P2860
Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Targeting cholesteryl ester tr ...... ent of cardiovascular disease.
@ast
Targeting cholesteryl ester tr ...... ent of cardiovascular disease.
@en
type
label
Targeting cholesteryl ester tr ...... ent of cardiovascular disease.
@ast
Targeting cholesteryl ester tr ...... ent of cardiovascular disease.
@en
prefLabel
Targeting cholesteryl ester tr ...... ent of cardiovascular disease.
@ast
Targeting cholesteryl ester tr ...... ent of cardiovascular disease.
@en
P1476
Targeting cholesteryl ester tr ...... ent of cardiovascular disease.
@en
P2093
John J P Kastelein
Philip J Barter
P304
P356
10.1016/J.JACC.2005.09.042
P407
P577
2006-01-18T00:00:00Z